louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02717767: Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in ICU
Official title: Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in Intensive Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pneumonia
Keywords: pneumonia
diagnosis
prognosis
tracheal aspirate
bronchoalveolar lavage
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2016-03-24
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients in intensive care units

Brief summary: The diagnosis of pneumonia is challenging in Intensive Care Unit. The auto-fluorescence of white corpuscles is altered during pneumonia. In presence of bacterial growth on lung samples, the measure of autofluorescence of white corpuscles could help the clinicians to discriminate bacterial colonization from acute infection.


Eligibility criteria: Inclusion Criteria:

* Hospitalization in intensive care units
* Mechanical ventilation
* Age \> 18 years
* Collection of a lung sample for bacteriological analysis for the suspicion of a first episode of lung infection.

Exclusion Criteria:

* Refuse to participate

Primary outcomes:
measure: Pneumonia
timeFrame: 28 days
Secondary outcomes:
measure: Clinical Pulmonary Infection Score > 6
timeFrame: day 3
measure: Acute respiratory distress syndrome
timeFrame: day 90
measure: Duration of mechanical ventilation
timeFrame: day 90
measure: Intensive Care unit Length of stay
timeFrame: day 90
measure: Mortality
timeFrame: day 90
Other outcomes:
Locations:
city: Blois
country: France
facility: Blois Hospital
city: Saint-Brieuc
country: France
facility: Saint-Brieuc Hospital
city: Saint-Nazaire
country: France
facility: Saint-NazaireHospital
city: Vannes
country: France
facility: Vannes Hospital
Study officials:
affiliation: Nantes University Hospital
name: Antoine ROQUILLY, PH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Monsel A, Lecart S, Roquilly A, Broquet A, Jacqueline C, Mirault T, Troude T, Fontaine-Aupart MP, Asehnoune K. Analysis of autofluorescence in polymorphonuclear neutrophils: a new tool for early infection diagnosis. PLoS One. 2014 Mar 21;9(3):e92564. doi: 10.1371/journal.pone.0092564. eCollection 2014.
Clinical trial NCT02712567: SARC021C: A Continuation Study of TH-CR-406/SARC021
Official title: A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Soft Tissue Sarcoma
Lead sponsor: Sarcoma Alliance for Research through Collaboration
Sponsor class: OTHER
Collaborators: name: Threshold Pharmaceuticals
First posted: 2016-03-18
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.

Detailed description: The goal of this study is to provide continuation therapy with TH-302 to patients with soft tissue sarcomas who obtained response or stabilization of disease with prior treatment on TH-CR-406/SARC021 protocol. After written informed consent has been obtained and eligibility has been established, patients will receive the study drug as part of the continuation study. Patients will receive treatment on study as long as they have clinical benefit and do not experience unacceptable toxicity.

Eligibility criteria: Inclusion Criteria:

* Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee.
* Previously enrolled on the TH-CR-406/SARC021 protocol and benefiting from treatment.
* Study investigator deems continued participation is appropriate based on overall health of the patient.

Exclusion Criteria:

* Any of the criteria for study discontinuation are met.
* Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study.
* Unwillingness or inability to comply with the study protocol for any reason.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00970567: Ketoacidosis in Individuals With Type I Diabetes Mellitus (T1DM)
Official title: Ketoacidosis in Individuals With T1DM
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 1 Diabetes
Keywords: therapy after positive ketone bodies in the blood
timepoint of diagnosis
timepoint of metabolic normalisation
Lead sponsor: Charite University, Berlin, Germany
Sponsor class: OTHER
Collaborators: name: Abbott
First posted: 2009-09-02
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to investigate individuals with type 1 diabetes who were disconnected from their insulin pump and insulin therapy was started again after positive ketones (U) in the urine or blood β-hydroxybutyrate.

Detailed description: Individuals with type 1 diabetes were disconnected from their insulin pump and insulin therapy was started again after positive ketones (U) in the urine or blood β-hydroxybutyrate with different therapy regimens after positive blood ketones.

Eligibility criteria: Inclusion Criteria:

* type 1 diabetes

Exclusion Criteria:

* severe hypo- or hyperglycemia during last 6 months
* acute illness

Primary outcomes:
measure: glucose metabolism, time course of positive ketone bodies
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité-Universitätsmedizin Berlin, Department of Endocrinology, Diabetes and Nutrition
Study officials:
affiliation: Charité, CBF
name: Joachim Spranger, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01213667: Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
Official title: Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Macular Degeneration
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2010-10-04
Enrollment: 110
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.


Eligibility criteria: Inclusion Criteria:

* active subfoveal CNV related to exudative age-related macular degeneration (all subforms)
* age \> 60 years
* visual acuity \> 20/400
* no previous treatment for AMD

Exclusion Criteria:

* any previous AMD therapy
* other CNV types (myopic, parapapillary)
* contraindication for ranibizumab treatment
* prior study participation for AMD
* pregnancy / premenopausal women

Primary outcomes:
measure: Visual acuity
timeFrame: 2 years
Secondary outcomes:
measure: Association between treatment response and genotype
timeFrame: 2 years
measure: Changes in OCT central retinal thickness / retinal volume
timeFrame: 2 years
measure: Association between treatment application delay and visual outcome
timeFrame: 2 years
measure: Association between re-treatment necessity / frequency and intraocular cytokine profiles
timeFrame: 2 years
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University Center of Ophthalmology
state: NRW
Study officials:
affiliation: Center of Ophthalmology, University of Cologne
name: Philipp S Muether, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016 Nov;100(11):1494-1498. doi: 10.1136/bjophthalmol-2015-308264. Epub 2016 Feb 17.
citation: Saunders DJ, Muether PS, Fauser S. A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. Br J Ophthalmol. 2015 Nov;99(11):1554-9. doi: 10.1136/bjophthalmol-2015-306771. Epub 2015 May 8.
citation: Koch KR, Muether PS, Hermann MM, Hoerster R, Kirchhof B, Fauser S. Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD. Graefes Arch Clin Exp Ophthalmol. 2012 Feb;250(2):201-9. doi: 10.1007/s00417-011-1792-8. Epub 2011 Sep 8.
Clinical trial NCT04409067: Masticatory Muscle Activity in Patients With Pain-related Temporomandibular Disorders
Official title: The Use of Electromyography in the Assessment of Masticatory Muscle Activity in Patients With Pain-related Temporomandibular Disorders
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: TMD
Keywords: masticatory muscles
surface electromyography
muscle activity
Lead sponsor: Pomeranian Medical University Szczecin
Sponsor class: OTHER
First posted: 2020-06-01
Enrollment: 90
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The subjects were selected from patients who had been referred to the Orthodontic Clinic in Szczecin, Poland for orthodontic treatment.

Brief summary: The aim of this study was to evaluate masticatory muscle electrical activity in patients with pain-related and pain-free temporomandibular disorders (TMD) as well as in subjects with no TMD. Ninety children with mixed dentition were recruited to the study. Of this total, 30 subjects were diagnosed with pain-related TMD, 30 with pain-free TMD, and 30 without TMD. We used Axis I of the Research Diagnostic Criteria for TMD (RDC/TMD) to assess the presence of TMD in the examined children. The electromyographical (EMG) potentials of the temporalis and masseter muscles were measured with a DAB-Bluetooth Instrument (Zebris Medical GmbH, Germany) at rest and during maximum voluntary clenching (MVC).


Eligibility criteria: Inclusion Criteria:

* mixed dentition (the subjects should be aged between 7 and 12 years)
* consent to participate voluntarily in the study

Exclusion Criteria:

* subjects who had undergone orthodontic or masticatory motor system dysfunction treatment, had systemic or rheumatologic diseases, a history of mouth breathing, surgery, traumas or malformations in the head and neck region

Primary outcomes:
measure: Electromyographic analysis of the masticatory muscles in patients with pain-related temporomandibular disorders
timeFrame: For a single subject the whole EMG examination was taken 40 minutes.
Secondary outcomes:
Other outcomes:
Locations:
city: Szczecin
country: Poland
facility: Pomeranian Medical University, Department of Orthodontics
Study officials:
References:
Clinical trial NCT00681967: Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
Official title: Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Head and Neck Cancer
Keywords: squamous cell cancer of the head & neck
Gefitinib
IRESSA
EGFR Inhibitor
EGFR-tyrosine kinase inhibitor
Subjects with histologically proven squamous cell cancer of the head & neck
Cohort 1:qualifying for postoperative radiotherapy
(pT3, pT4, pN2b, pN2c, pN3).
Cohort 2:qualifying for definite chemoradiotherapy
(Lateral oropharynx, tonsils: T1N2b-3, T2N1-3, T3any N;
Base of tongue, vallecula: T1N1-3, T2-4 any N; Oral cavity,
glottic and supraglottic larynx; Any TN1-3, T3-4 any N;
Hypopharynx: T1N1-3, T2-4 and N)
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-05-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Age over 18 years
* Histologically proven squamous cell cancer of the head \& neck (SCCHN)
* Indication for postoperative Radiotherapy: pT3, pT4, pN2b, pN2c, pN3

Exclusion Criteria:

* Hypersensitivity to ZD1839 or any of the excipients of this product
* Tumour stage M1
* Co-existing malignancies diagnosed within the last 5 years. Exceptions: basal cell carcinoma, cervical cancer in situ
* Absolute neutrophil counts \<1.5 x 109

Primary outcomes:
measure: To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
Secondary outcomes:
measure: Both cohorts overall survival (OS) local control (LC) rate at six months and at one year
measure: Cohort 1 only time-to-recurrence (TTR)
measure: Cohort 2 only time-to-progression (TTP). Complete Response (CR) rate time to treatment failure (TTF)
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Research Site
city: Bern
country: Switzerland
facility: Research Site
Study officials:
affiliation: University Hospital of Basel
name: Christoph Rochlitz, Prof Dr med
role: PRINCIPAL_INVESTIGATOR
affiliation: AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
name: Madeleine Billeter, MD
role: STUDY_DIRECTOR
affiliation: AstraZeneca AG, Grafenau 10; 6300 Zug; Switzerland
name: Verena Renggli
role: STUDY_CHAIR
References:
Clinical trial NCT05571267: Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
Official title: A Phase 2A Randomized Open-Label Controlled Trial to Assess the Safety of Zimura™ (Anti-C5 Aptamer) Administered in Combination With Anti-VEGF Therapy in Treatment Experienced Patients With Neovascular Age-Related Macular Degeneration
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Neovascular Age-Related Macular Degeneration
Keywords: Neovascular age-related macular degeneration (NVAMD)
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2022-10-07
Enrollment: 1
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment experienced subjects with neovascular age-related macular degeneration (AMD)


Eligibility criteria: Inclusion Criteria:

* Treatment experienced subjects defined as subjects with 1 prior dose of same intravitreal anti-VEGF therapy given within the past 8 weeks for neovascular age-related macular degeneration (NVAMD) in the study eye. There must be \< 0 letters of improvement in Snellen (not ETDRS Snellen equivalent) visual acuity since the start of anti-VEGF treatment.
* Presence of subfoveal active choroidal neovascularization (CNV)

Exclusion Criteria:

* Intravitreal treatment in the study eye prior to the Day 1 visit, regardless of indication, with the exception of the 1 prior anti-VEGF injections.
* Presence of other causes of choroidal neovascularization, including pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis.
* Non-pharmacologic treatment (intraocular surgery or thermal laser) within three months of trial entry.
* Prior thermal laser in the macular region, regardless of indication.
* Ocular or periocular infection in the past twelve weeks.
* History of any of the following conditions or procedures in the study eye: rhegmatogenous retinal detachment, pars plana vitrectomy, filtering surgery, glaucoma drainage device, or corneal transplant.
* Previous therapeutic radiation in the region of the study eye.
* Evidence of diabetic retinopathy

Primary outcomes:
measure: Percentage of Participants With >0 Letter Loss
timeFrame: Month 12
measure: Percentage of Participants With >0 Letter Loss
timeFrame: Month 18
measure: Percentage of Participants With >5 Letter Loss
timeFrame: Month 12
measure: Percentage of Participants With >5 Letter Loss
timeFrame: Month 18
measure: Percentage of Participants With >10 Letter Loss
timeFrame: Month 12
measure: Percentage of Participants With >10 Letter Loss
timeFrame: Month 18
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: IVERIC bio, Inc.
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03345667: Assessment of Color Vision in Diabetic Patients
Official title: Assessment of Color Vision in Diabetic Patients Before and After the Use of Anti-vegf in the Treatment of Diabetic Macular Edema
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Retinopathy, Diabetic
Lead sponsor: Instituto de Olhos de Goiania
Sponsor class: OTHER
First posted: 2017-11-17
Enrollment: 30
Sex: ALL
Minimum age (years): 1
Maximum age (years): 100
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema. Using the Ishirara's test to evaluate the possible visual loss.

Brief summary: Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema


Eligibility criteria: Inclusion Criteria:

* Having diabetic retinopathy with macular edema

Exclusion Criteria:

* Not having diabetic retinopathy with macular edema

Primary outcomes:
measure: Assessment of color vision in diabetic patients before and after the use of anti-vegf in the treatment of diabetic macular edema
timeFrame: 3 months
Secondary outcomes:
measure: Frame between the injections
timeFrame: 1 months
Other outcomes:
Locations:
city: Goiânia
country: Brazil
facility: Instituto de Olhos de Goiania
state: Goias
Study officials:
References:
Clinical trial NCT01161667: Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions
Official title: A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Tablets Under Fasted Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine
Lead sponsor: West-Ward Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2010-07-13
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The objective of this study was to prove the bioequivalence of Naratriptan Hydrochloride Tablet under fasted conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion Criteria:

* Positive test for HIV, Hepatitis B, or Hepatitis C.
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to naratriptan hydrochloride or any comparable or similar product.

Primary outcomes:
measure: bioequivalence determined by statistical comparison Cmax
timeFrame: 9 days
Secondary outcomes:
Other outcomes:
Locations:
city: Tacoma
country: United States
facility: Charles River Northwest Kinetics
state: Washington
Study officials:
affiliation: Charles River Northwest Kinetics
name: Linda Bavisotto, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04964167: Indocyanine-green Mediated Photosensitizer VS Aloe Vera Gel: Adjunct Therapy to Scaling and Root Planing in Patients With Chronic Periodontitis
Official title: Indocyanine-green Mediated Photosensitizer VS Aloe Vera Gel: Adjunct Therapy to Scaling and Root Planing in Patients With Chronic Periodontitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Periodontitis
Periodontal Inflammation
Lead sponsor: Riyadh Elm University
Sponsor class: OTHER
Collaborators: name: Salah Abdalkreem Almohana
name: Abdulmohsen Khalid Alanazi
name: Abdulelah Khalid Alanazi
name: Alhanouf Abdulkarem Almohana
First posted: 2021-07-15
Enrollment: 150
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: For proving the potential of tropical medicaments on clinical parameters of periodontitis, a comprehensive assessment is required between therapeutic medicaments. The main aim of the study was to clinically evaluate and compare the efficacy of indocyanine green mediated photodynamic therapy (PDT) and aleo vera (AV) extract when used as an adjunct therapy to scaling and root planning (SRP) for treatment of chronic periodontitis.

One hundred and fifty patients included in this study were randomly distributed in three treatment groups Group I (SRP), Group II (SRP+PDT) and Group III (SRP+AV). Four clinical parameters plaque index (PI), bleeding on probing (BoP), periodontal (PD) pocket depth and clinical attachment level (CAL) were evaluated at three time points baseline, 3rd and 6th month respectively. Additionally the amount of three inflammatory cytokines IL-6, IL-8 and TNF- α in gingival crevicular fluid (GCF) was identified using enzyme linked immune-sorbent assay (ELISA) technique.


Eligibility criteria: Inclusion Criteria:

* age of ≥ 30 years;
* ≥ 20 natural teeth; and
* chronic-periodontitis (≥ 3 mm of CAL and PD pocket depth respectively on at least 30% of dental sites).

Exclusion Criteria:

* chronic systemic diseases;
* PD therapy during last 6 months;
* habitual use of chewable and non-chewable tobacco (smoking);
* alcohol consumers; or
* use of particular medications during last three months (steroidal and non-steroidal drugs/ anti-biotic/ anti-depressants)

Primary outcomes:
measure: Clinically Evaluating the Effects of Topical Indocyanine-green Mediated Photosensitizer VS Aloe vera Gel: Adjunct therapy to Scaling and Root Planing in Patients with Chronic Periodontitis
timeFrame: 9 months
measure: IL-6 concentration in pg/ml
timeFrame: 6 months
measure: IL-8 concentration in pg/ml
timeFrame: 6 months
measure: TNF-α levels in pg/ml
timeFrame: 6 months
measure: Periodontal pocket depth in mm
timeFrame: 6 months
measure: Clinical attachment loss in mm
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Liaquat College of Medicine and Dentistry
city: Riyadh
country: Saudi Arabia
facility: Riyadh Elm University
Study officials:
References: